for educational and safety purposes
Every compound in the sci-wiki that affects pain; the ones you can source are floated to the front, then the reference-only entries. Tap any for the full entry, mechanism, and outlets.
11 sourced · 34 reference
Taltirelin (TA-0910, brand name Ceredist) is a synthetic, metabolically stable analog of thyrotropin-releasing hormone (TRH), the three-residue hypothalamic peptide. It was developed by Tanabe Seiyaku and approved in Japan in 2000 for spinocerebellar degeneration, where it is taken orally to help with ataxia and related symptoms. The interesting thing about taltirelin is that it was engineered to keep the central nervous system effects of TRH while shedding most of the hormonal ones; it is roughly 10 to 100 times more potent than native TRH at driving CNS arousal, yet its effect on thyroid hormone release is much weaker. It also lasts far longer in the body because it resists the enzymes that chew up natural TRH within minutes. Outside its approved use it gets discussed in nootropic and biohacker circles as a wakefulness-promoting, pro-cholinergic "analeptic" and neuroprotective agent, and there is a real preclinical literature behind those claims (Parkinson's models, ischemia, pain, respiratory stimulation). Human data outside spinocerebellar degeneration is thin, so most of what you read about it as a cognitive enhancer is extrapolation from animal work.
Dermorphin is a naturally occurring opioid peptide, a chain of seven amino acids first isolated from the skin of South American frogs of the genus Phyllomedusa. It is among the most potent and selective mu-opioid agonists known, reported to be many times stronger than morphine, and it is one of very few peptides made by a vertebrate to contain a D-amino acid, a D-alanine residue installed by post-translational epimerization that is essential to its potency and its resistance to protease breakdown. Dermorphin is not an approved medicine; it is used in research and is known for its illicit use as a doping agent in horse racing.
MSM (methylsulfonylmethane), also known as dimethyl sulfone, is a naturally occurring organosulfur compound and oxidation product of dimethyl sulfoxide that is present in trace amounts in many foods and is widely sold as a dietary supplement. Its reported anti-inflammatory and antioxidant actions are attributed to suppression of NF-kB signaling and downstream pro-inflammatory mediators, together with scavenging of reactive oxygen species and support of endogenous antioxidant capacity. Several randomized controlled trials in knee osteoarthritis report modest improvements in pain and physical function, and the compound is generally recognized as safe and well tolerated at doses of up to several grams daily. Preclinical studies have additionally examined effects on exercise-related oxidative stress, allergic inflammation and cancer-cell biology, including induction of apoptosis and sensitization of tumor cells to chemotherapy, though the overall clinical evidence base remains limited.
L-THP (levo-tetrahydropalmatine) is a plant alkaloid from Corydalis and related herbs with a long history in traditional Chinese medicine for its calming, sedative, and pain-relieving properties. Modern research has clarified its mechanism as a dopamine receptor modulator, and it has been carried all the way into a human clinical study for cocaine use disorder, an unusually strong evidence base for a botanical compound. For those exploring natural approaches to relaxation, sleep, and discomfort, L-THP is a genuinely well-studied and intriguing choice.
Amitriptyline is a tricyclic antidepressant introduced in the early 1960s, originally for major depression and now used at least as often for chronic pain conditions. It relieves symptoms by increasing the availability of the neurotransmitters serotonin and norepinephrine, while also blocking histamine, acetylcholine, and adrenergic receptors, which accounts for both its sedating quality and many of its side effects [1]. Common uses today include neuropathic pain, fibromyalgia, and the prevention of migraine and tension headaches, in addition to depression [3][4].
Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) that selectively targets the cyclooxygenase-2 enzyme, used mainly to relieve pain and inflammation in arthritis and related conditions [1][2]. By focusing on COX-2 while largely sparing COX-1, it aims to ease inflammation with a lower risk of stomach ulcers than older, nonselective NSAIDs [2]. Discovered at Searle and approved in the United States in 1998, it is sold under the brand name Celebrex and is now widely available as a generic [1]. Like other NSAIDs it carries cardiovascular and other risks that shape how it is prescribed [1][3].
Duloxetine is a balanced serotonin-norepinephrine reuptake inhibitor, marketed chiefly as Cymbalta since 2004, approved for major depression and generalized anxiety as well as several chronic pain conditions. Its analgesic action reflects potentiation of descending serotonergic and noradrenergic pathways that dampen pain signaling in the spinal cord, an effect largely separate from its antidepressant activity. Randomized trials support its use in diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain from osteoarthritis and low back pain, and it is the agent with the strongest randomized evidence recommended by oncology guidelines for chemotherapy-induced peripheral neuropathy. Through the same monoaminergic facilitation of pudendal motor neurons in Onuf's nucleus, duloxetine strengthens urethral sphincter tone and is used in some countries for stress urinary incontinence. It is a prescription-only medicine, available generically, and appears on the World Health Organization list of essential medicines.
Ibuprofen is a propionic acid nonsteroidal anti-inflammatory drug that relieves pain, fever, and inflammation by reversibly and competitively inhibiting both cyclooxygenase isoforms, COX-1 and COX-2, thereby reducing synthesis of prostaglandins from arachidonic acid. Marketed as a racemate, it undergoes a distinctive unidirectional metabolic inversion in which the inactive R-enantiomer is converted in vivo to the pharmacologically active S-form. Because it competes for the same catalytic site as aspirin on platelet COX-1, ibuprofen can transiently blunt aspirin's irreversible antiplatelet effect, a clinically relevant interaction in patients taking low-dose aspirin for cardioprotection. Large randomized evidence from the PRECISION trial found ibuprofen non-inferior in cardiovascular safety to naproxen and celecoxib, though with comparatively higher gastrointestinal and renal event rates; it remains one of the most widely used over-the-counter medicines worldwide.
Indomethacin, also spelled indometacin, is a potent nonsteroidal anti-inflammatory drug (NSAID) of the indole acetic acid class, used to relieve pain, fever, and inflammation. It is a mainstay for acute gout, ankylosing spondylitis, and other inflammatory arthritis, and it also has specialized roles in closing a patent ductus arteriosus in premature infants and in a distinctive group of indomethacin-responsive headaches. First introduced in the 1960s, it is considered one of the stronger NSAIDs and appears on the World Health Organization list of essential medicines.
Ketorolac is a nonsteroidal anti-inflammatory drug (NSAID) noted for unusually strong analgesic activity, used for the short-term management of moderate to severe pain. Chemically a pyrrolizine carboxylic acid derivative, it is often given by injection after surgery, where it can relieve pain comparably to opioids such as morphine while sparing opioid use [1]. Because of a heightened risk of gastrointestinal, kidney, and bleeding complications, its use is deliberately limited to short courses [1].
Paracetamol, known as acetaminophen in the United States, is one of the most widely used pain and fever medicines in the world, relieving mild to moderate pain with little of the stomach irritation seen with nonsteroidal anti-inflammatory drugs. Remarkably, after more than a century its exact mechanism is still debated; a leading explanation is that in the brain it is converted to a metabolite, AM404, that acts on the endocannabinoid and TRPV1 systems and inhibits central prostaglandin synthesis, and AM404 has been detected in human cerebrospinal fluid after a normal dose. Very safe at recommended doses, it can cause severe liver injury in overdose and is a leading cause of acute liver failure; a widely discussed concern about prenatal use and child neurodevelopment was substantially weakened by a large sibling-controlled study pointing to familial confounding rather than causation.
2-Fluorodeschloroketamine (2-FDCK, 2F-DCK) is an arylcyclohexylamine dissociative and a fluorinated analog of ketamine in which the aromatic chlorine is replaced by fluorine, and it is presumed to share ketamine's mechanism as an N-methyl-D-aspartate (NMDA) receptor antagonist. It has circulated widely as an inexpensive research chemical producing a broadly ketamine-like dissociative state, and its extensive metabolism has been mapped in human liver microsomes, urine, and hair, with nor-2F-DCK identified as a principal metabolite. Addictovigilance surveillance has linked ketamine analogues including 2-FDCK to serious neurological and psychiatric events and to recorded deaths, and case reports describe emergency presentations in a dissociated state after insufflation. Like other arylcyclohexylamines, it carries risks of compulsive redosing and, with chronic use, urinary tract and bladder toxicity.
Alphadolone (alfadolone; clinically alphadolone acetate) is a synthetic neuroactive pregnane steroid (a laboratory-made steroid that acts on the nervous system) which potentiates the GABA-A receptor, the brain's principal fast inhibitory chloride channel, to produce sedation and anaesthesia. It is best known as the minor component of the intravenous anaesthetic Althesin (for humans) and Saffan (for animals), where it was combined with the more potent alfaxalone in a 3:1 ratio, added chiefly to improve the poor water solubility of alfaxalone while still contributing roughly half of that agent's anaesthetic potency in its own right. Both preparations were dissolved in the surfactant Cremophor EL, whose tendency to trigger histamine release and anaphylactoid reactions led to the withdrawal of Althesin from human use in 1984. Alphadolone later attracted independent research interest because, unlike alfaxalone, it produces spinally mediated analgesia without sedation when given by mouth or intraperitoneally, an effect thought to depend on an analgesic metabolite formed in the liver.
BIA 10-2474 is an investigational, orally active fatty acid amide hydrolase (FAAH) inhibitor developed by the Portuguese pharmaceutical company Bial as a candidate treatment for chronic pain, anxiety, and mood disorders. By blocking FAAH, the enzyme that degrades the endocannabinoid anandamide, it was intended to raise endocannabinoid tone and produce analgesic and anxiolytic effects. In January 2016 a Phase 1 healthy-volunteer trial in Rennes, France produced an unanticipated, rapidly progressive neurologic syndrome in the high repeated-dose cohort: one volunteer died and several others were hospitalized with symmetric brain lesions. Development was halted, and subsequent proteomic work showed the compound is a promiscuous inhibitor of multiple lipases and off-target enzymes rather than a selective FAAH blocker. It is now regarded as a landmark case study in drug-safety science and is not available or used outside that historical and investigational context.
CP-55,940 is a synthetic non-classical cannabinoid that acts as a potent, non-selective full agonist at the CB1 and CB2 cannabinoid receptors. Developed by Pfizer in the 1970s during a search for cannabinoid-based analgesics, it lacks the classic tricyclic dibenzopyran ring of THC yet reproduces the full cannabinoid pharmacological profile with far greater potency. Its tritiated form, [3H]CP-55,940, became the standard radioligand used to detect, clone, and map cannabinoid receptors, making the compound a foundational reference tool in endocannabinoid research rather than a therapeutic or consumer product.
Deschloroketamine (DCK) is an arylcyclohexylamine dissociative and a ketamine analogue in which the aromatic chlorine of ketamine is removed. Like ketamine and related arylcyclohexylamines, it is presumed to act principally as an antagonist at the N-methyl-D-aspartate (NMDA) glutamate receptor, producing dissociative and anaesthetic-like effects, and users report a comparatively longer duration than ketamine. It emerged on the new psychoactive substance market alongside the fluorinated analogue 2-fluorodeschloroketamine (2F-DCK), of which DCK is also a metabolite, and forensic studies have mapped its extensive hepatic metabolism and urinary and hair biomarkers. Addictovigilance and toxicology reports associate DCK and its congeners with dissociation, impaired consciousness, redosing, and serious outcomes including fatalities, and chronic heavy use carries the urinary and bladder toxicity concerns characteristic of the ketamine class.
Devil's claw is a herbal medicine prepared from the tuberous roots of Harpagophytum procumbens, a plant of the sesame family (Pedaliaceae) native to the semiarid regions of southern Africa. The remedy takes its name from the small hooked barbs that cover the plant's woody fruit, and its root preparations are valued chiefly for iridoid glycosides such as harpagoside. In traditional southern African medicine and in modern European phytotherapy, devil's claw is used mainly to ease musculoskeletal pain, particularly osteoarthritis and lower back pain. It is marketed as a dietary supplement or traditional herbal product rather than an approved pharmaceutical drug.
Dimiracetam is a synthetic bicyclic compound of the racetam family, related to the nootropic drug piracetam. It was originally developed as a cognition enhancer but has attracted most of its research attention as a candidate treatment for neuropathic pain, showing broad and long-lasting activity in animal models of several nerve-pain conditions, including pain caused by chemotherapy; this activity is attributed to reduced release of the excitatory neurotransmitter glutamate. It remains an investigational agent and is not an approved medicine.
Dronabinol is a pharmaceutical cannabinoid that consists of synthetically produced (-)-trans-delta-9-tetrahydrocannabinol (delta-9-THC), the principal psychoactive constituent of Cannabis sativa, formulated as an oral agent. Marketed as Marinol (sesame-oil capsules) and Syndros (an oral solution), it is approved by the U.S. FDA for chemotherapy-induced nausea and vomiting refractory to conventional antiemetics and for anorexia associated with weight loss in patients with AIDS. It acts as a partial agonist at the CB1 and CB2 cannabinoid receptors of the endocannabinoid system, producing appetite stimulation, antiemetic effects, analgesia, and mood elevation. Dronabinol capsules were rescheduled from Schedule II to the less restrictive Schedule III in the United States, while the Syndros oral solution remains Schedule II.
Esketamine is the S-enantiomer of ketamine, the half of the racemic mixture that binds the NMDA receptor several times more tightly, and it is the only member of the ketamine family approved as an antidepressant. As the nasal spray Spravato it is licensed for treatment-resistant depression alongside an oral antidepressant, and for depressive symptoms in adults with active suicidal ideation. Administration is supervised: the dose is taken in a certified setting and the patient is observed for two hours afterwards, because sedation, dissociation and a transient rise in blood pressure are expected rather than rare. It is a real antidepressant with a real effect size and a genuinely inconvenient delivery model.
Flurbiprofen is a nonsteroidal anti-inflammatory drug (NSAID) in the same propionic-acid family as ibuprofen. It is used for pain, inflammation, and stiffness, comes as tablets, an eye drop (to keep the pupil open during surgery), and topical and lozenge forms for sore throat. Like other NSAIDs, it works by dialing down the body's production of prostaglandins, the messengers behind much inflammation, pain, and fever.
Ketamine is a dissociative anesthetic that turned into the most important antidepressant discovery in fifty years. It blocks the NMDA glutamate receptor, which is what produces anesthesia without suppressing breathing and made it a battlefield and emergency drug from 1970 onward [1]. The finding that matters now came around the turn of the century: a single sub-anesthetic dose can lift severe, treatment-resistant depression within hours rather than weeks, an effect no monoamine antidepressant produces [3][4]. Its S-enantiomer, esketamine, is approved for that use as a nasal spray. Cognition is the more nuanced half of the story; repeated supervised infusions have not been shown to impair it and several measures improve as depression lifts, while heavy unsupervised use is reliably associated with memory problems [28][30]. It remains a controlled substance with real dependence and bladder toxicity risk outside clinical use.
Kratom is a herbal preparation made from the leaves of Mitragyna speciosa, a tropical evergreen tree in the coffee family that is native to Southeast Asia. The leaves contain the indole alkaloids mitragynine and 7-hydroxymitragynine, which act as partial agonists at the μ-opioid receptor and produce stimulant-like effects in smaller amounts and opioid-like sedation and pain relief in larger ones. Traditionally chewed or brewed by laborers in Thailand, Malaysia, and neighboring countries, it has since spread worldwide and is now marketed as a botanical supplement, though its safety and legal standing remain contested.
LIT-001 is the first non-peptide oxytocin receptor agonist that reaches the brain and changes behaviour after an ordinary injection into the body, rather than having to be delivered into the skull. Oxytocin itself is a therapeutic dead end for brain use for three separate reasons, and this molecule was built to defeat all three at once. It has never been given to a human being.
Matrine is a tetracyclic quinolizidine alkaloid obtained mainly from plants of the genus Sophora, especially the roots of Sophora flavescens, known in Chinese medicine as Kushen. It is one of the principal active constituents of these long-used herbal materials and has been investigated for a wide range of pharmacological effects, including anticancer, anti-inflammatory, antiviral, and antiparasitic activities [1][3]. It occurs alongside the closely related alkaloid oxymatrine, and although widely studied in the laboratory, its clinical use is constrained by questions about toxicity and bioavailability [1].
Menthol is a naturally occurring organic compound of the monoterpenoid class, a waxy crystalline secondary alcohol best known for the cooling sensation it produces. It is obtained mainly from the essential oils of mint plants such as peppermint and corn mint, and it is also manufactured synthetically on a large scale. Widely used in topical pain relievers, cough and cold remedies, oral care products, confections, and tobacco, menthol produces its characteristic coolness by activating the cold-sensing TRPM8 receptors of sensory nerves.
Methoxetamine (MXE) is an arylcyclohexylamine dissociative developed as a ketamine analog and widely sold as a research chemical before international bans. It acts as a potent uncompetitive antagonist at the NMDA glutamate receptor, binding the phencyclidine site within the channel pore to produce dissociative, anesthetic, and psychotomimetic effects; unlike ketamine it also engages serotonergic systems, raising cortical and accumbal serotonin and relying partly on 5-HT2 receptors for some of its sensorimotor effects. Its longer duration and greater intensity relative to ketamine, marketed misleadingly as "bladder friendly," were accompanied by reports of abuse, urinary and cerebellar toxicity, and fatal intoxications. Paradoxically, preclinical work has also identified rapid antidepressant-like effects mediated through glutamatergic and AMPA-receptor signaling, mirroring ketamine.
Nabilone is a synthetic cannabinoid (a structural analog of delta-9-tetrahydrocannabinol) that acts as an agonist at the cannabinoid CB1 and CB2 receptors. Marketed as Cesamet, it is approved in the United States, Canada, the United Kingdom and other countries for the treatment of severe nausea and vomiting associated with cancer chemotherapy that has failed to respond to conventional antiemetics. Unlike inhaled cannabis or plant-derived THC, nabilone is a single, orally administered, pharmaceutically standardized molecule, which gives it consistent dosing and a defined pharmacokinetic profile. Beyond its licensed antiemetic indication, it has been studied off-label for neuropathic and chronic non-cancer pain, fibromyalgia, PTSD-associated nightmares, and agitation in Alzheimer's disease, with mixed but frequently encouraging results. Nabilone is a Schedule II controlled substance in the United States and a prescription-only medicine.
Neurotrophin-3 (NT-3) is a naturally occurring protein belonging to the neurotrophin family, which also includes nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF). It supports the survival, growth, and differentiation of developing neurons and helps maintain certain nerve cells in the mature nervous system. Because of these roles, recombinant NT-3 has been investigated as a therapy for nerve and gastrointestinal disorders, although it is not an approved or consumer product.
Norketamine is the first and largest metabolite of ketamine, made by removing a single methyl group, and unlike most metabolites it is pharmacologically active in its own right. It blocks the NMDA receptor by the same non-competitive mechanism as its parent, at roughly a third to a fifth of the potency [1]. That matters clinically rather than academically: after oral or prolonged dosing, norketamine concentrations exceed ketamine's, so a meaningful share of the analgesia a patient experiences is coming from the metabolite rather than the drug that was given [2]. It also sits on the metabolic path to the hydroxynorketamines, which is where the antidepressant argument has moved.
OL-135 is a reversible, competitive fatty acid amide hydrolase (FAAH) inhibitor of the alpha-ketoheterocycle class, developed by the Boger laboratory at The Scripps Research Institute as a chemical tool to raise endogenous anandamide. Built around an electrophilic alpha-ketooxazole warhead (a pyridyl-activated ketone), it inhibits FAAH in the low-nanomolar range and is selective over other serine hydrolases. Unlike the irreversible carbamate inhibitor URB597, OL-135 binds the enzyme reversibly, forming a deprotonated hemiketal with the catalytic serine that mimics the tetrahedral reaction intermediate. In rodent studies it elevates brain anandamide and produces cannabinoid-receptor-mediated analgesia, anti-allodynia, anti-pruritic and anti-inflammatory effects without the overt psychoactivity of direct CB1 agonists. OL-135 remains an investigational research compound; it never advanced to human clinical trials, but it served as the lead scaffold for a large family of orally active, long-acting FAAH inhibitors.
Parthenolide is a naturally occurring sesquiterpene lactone found chiefly in the herb feverfew (Tanacetum parthenium). It is regarded as one of the main active constituents behind feverfew's traditional use for migraine, and in the laboratory it is known for blocking the inflammatory signaling protein NF-kB. It has drawn considerable research interest for anticancer activity, including against cancer stem cells, though poor water solubility has limited its development as a drug.
Peppermint oil is the essential oil distilled from peppermint (Mentha x piperita), an aromatic hybrid of watermint and spearmint. Rich in menthol, it is used as a flavoring and fragrance and, in medicine, most notably as an antispasmodic remedy for irritable bowel syndrome, usually taken as enteric-coated capsules. It produces the familiar cooling sensation of mint and has a long history in both cooking and traditional herbal practice.
PF-3845 is a highly selective, covalent fatty acid amide hydrolase (FAAH) inhibitor developed by Pfizer as a pharmacological tool to augment endocannabinoid signaling in vivo. By carbamylating the serine nucleophile of FAAH, the enzyme responsible for degrading the endocannabinoid anandamide, PF-3845 raises brain and peripheral levels of anandamide and related N-acylethanolamines for up to 24 hours after a single dose. It is widely used in preclinical neuroscience to probe endocannabinoid contributions to pain, inflammation, anxiety, and nausea, and remains an investigational research compound rather than an approved drug.
Serrapeptase, also called serratiopeptidase, is a proteolytic enzyme originally isolated from bacteria (Serratia species) found in the gut of the silkworm, where it helps the emerging moth dissolve its cocoon. It is sold as a dietary supplement and promoted for anti-inflammatory, anti-swelling, and pain-relieving effects and for thinning mucus. Although it has been used clinically in Japan and parts of Europe, the supporting evidence is limited and generally of low quality.
URB597, also known as KDS-4103, is a potent and selective inhibitor of fatty acid amide hydrolase (FAAH), the enzyme that breaks down the endocannabinoid anandamide. By blocking FAAH, URB597 raises anandamide levels and amplifies endocannabinoid signaling, producing anxiolytic, antidepressant-like, and analgesic effects in animal models without the full intoxicating profile of direct cannabinoid agonists [1][2][3]. It is one of the most extensively used FAAH inhibitor research tools.
Morphine is a potent opioid analgesic and the principal alkaloid of opium, the dried latex of the opium poppy (Papaver somniferum). It relieves moderate to severe pain by activating opioid receptors in the brain and spinal cord, and it has been a mainstay of pain medicine since it was first isolated in the early nineteenth century. A controlled substance on the World Health Organization's list of essential medicines, morphine is highly effective but carries substantial risks of dependence, addiction and potentially fatal respiratory depression.
Codeine is an opioid medication and a naturally occurring alkaloid found in the opium poppy, used to relieve mild to moderate pain, to suppress coughing and to treat diarrhoea [1]. It is a prodrug: the body converts a portion of it into morphine, which produces most of its pain-relieving effect by acting on mu-opioid receptors [1][3]. First isolated in 1832, it remains one of the most widely used opioids and appears on the World Health Organization's list of essential medicines, but it is a controlled substance with real risks of dependence and, in some people, dangerous sensitivity [1][2].
Oxycodone is a semi-synthetic opioid analgesic used to treat moderate to severe pain. Derived from the opium alkaloid thebaine and first synthesized in 1916, it acts on the mu-opioid receptor to relieve pain but carries a high potential for tolerance, dependence, and misuse. It is a controlled substance in most countries and is available in immediate-release and controlled-release forms, sometimes combined with non-opioid analgesics.
Hydrocodone is a semisynthetic opioid derived from the naturally occurring alkaloids codeine and thebaine, used medically to relieve moderate to severe pain and to suppress cough. It is most often taken by mouth, frequently combined with a non-opioid analgesic such as acetaminophen or ibuprofen in products like Vicodin and Norco. Like other opioids it carries a substantial risk of dependence, addiction, and life-threatening respiratory depression, and it is tightly controlled as a scheduled substance.
Fentanyl is a powerful synthetic opioid used medically for anesthesia and for severe pain, including breakthrough cancer pain. It acts on mu-opioid receptors in the nervous system and is estimated to be roughly 50 to 100 times more potent than morphine. In recent years, illicitly manufactured fentanyl has become a leading cause of drug overdose deaths.
Tramadol is a centrally acting opioid analgesic used to treat moderate to moderately severe pain, set apart from typical opioids by a dual mechanism [1][2]. In addition to weakly activating the mu-opioid receptor, it inhibits the reuptake of the neurotransmitters serotonin and norepinephrine, so it also behaves somewhat like an antidepressant [2]. First marketed in the late 1970s and sold under names such as Ultram, it is a scheduled controlled substance in many countries.
Heroin (diacetylmorphine, or diamorphine in medicine) is a fast-acting semisynthetic opioid made by acetylating morphine. It is a prodrug; the body strips the acetyl groups off to release 6-monoacetylmorphine and morphine, which switch on mu-opioid receptors to produce pain relief, a rush of euphoria, and dangerous slowing of breathing.
Buprenorphine is a semisynthetic opioid that acts as a partial agonist at the mu-opioid receptor. It is widely used to treat opioid use disorder and is also used for acute and chronic pain. First developed in the 1960s from the poppy alkaloid thebaine, it is often combined with naloxone in formulations intended to discourage misuse.
Methadone is a synthetic opioid medication that acts mainly as an agonist at the mu-opioid receptor, with additional activity as an antagonist at the NMDA glutamate receptor. It is used both to treat opioid use disorder, where long-acting daily doses prevent withdrawal and reduce cravings, and to manage chronic and cancer pain. First synthesized in Germany in the late 1930s, methadone is distinguished among opioids by its long and variable duration of action, and it is listed as an essential medicine by the World Health Organization.